

KENSTATIN		
NYSTATIN ORAL SUSPENSION USP 100000 IU/ML		
MODULE I :	ADMINISTRATIVE PARTICULARS OF THE PRODUCT	
Document	1.3	Product Information

1.3 Product Information

1.3.1 Summary of Product Characteristics (SmPC)

1. Name of the medicinal product

1.1 (Invented) Name of the medicinal product

KENSTATIN (NYSTATIN ORAL SUSPENSION USP 100,000 IU/ML)

1.2 Strength

Each ml of reconstituted Suspension

contains: Nystatin USP 100000 IU

Excipients Q.S.

1.3 Pharmaceutical Form

Oral Suspension

2. Qualitative and Quantitative

Formula Batch Size: 1000 Lit.

Sr. No.	Name of Raw Material	Specification	Qty./ ml (mg)	Qty./ Bottle (mg)	Qty./ Batch (Kg)	Function
1.	Nystatin	USP	20.00	600.00	20.00	Antifungal
2.	Sorbitol 70% solution	BP	300.00	9000.00	300.00	Sweetner
3.	Sodium Methyl Paraben	BP	2.00	60.00	2.00	Preservative
4.	Sodium Propyl Paraben	BP	1.00	30.00	1.00	Preservative
5.	Sodium Benzoate	BP	1.00	30.00	1.00	Preservative
6.	Sodium Saccharine	BP	0.75	22.50	0.75	Sweetner
7.	Xanthan Gum	BP	2.00	60.00	2.00	Suspending agent
8.	Glycerin	BP	40.00	1200.00	40.00	Sweetner
9.	Colloidal Anhydrous Silica	BP	5.40	162.00	5.40	Glidant
10.	Bronopol	BP	0.25	7.50	0.25	Preservative
11.	Flavour Mix Fruit	IHS	2.50	75.00	2.50	Flavouring agent
12.	Flavour Peppermint	IHS	2.50	75.00	2.50	Flavouring agent
13.	Purified Water	BP	Q.S. to 1 ml	Q.S. to 30 ml	Q.S. to 1000 Lit.	Solvent

3. Pharmaceutical form

A Clear coloured flavoured Suspension.

KENSTATIN		
NYSTATIN ORAL SUSPENSION USP 100000 IU/ML		
MODULE I :	ADMINISTRATIVE PARTICULARS OF THE PRODUCT	
Document	1.3	Product Information

4. Clinical particulars

4.1 Therapeutic

Indication: Indications

The prevention and treatment of candidal infections of the oral cavity, oesophagus and intestinal tract.

The suspension also provides effective prophylaxis against oral candidosis in those born of mothers with vaginal candidosis.

4.2 Posology and method of administration: Posology

Oral Candidiasis

Infants (1 month to 2 years)

1ml should be dropped into the mouth four times a day.

Children (≥ 2 years) and adults

For the treatment of denture sores, and oral infections in children (≥ 2 years) and adults caused by candida albicans. 1ml of the suspension should be dropped into the mouth four times daily; it should be kept in contact with the affected areas as long as possible.

Intestinal candidiasis

Infants (1 month to 2 years)

1ml should be dropped into the mouth four times a day.

Adults

For the treatment of intestinal candidosis 5ml of the suspension should be dropped into the mouth four times daily.

Paediatric population (≥ 2 years)

1ml should be dropped into the mouth four times a day.

For prophylaxis a total daily dosage of 1 million units has been found to suppress the overgrowth of candida albicans in patients receiving broad-spectrum antibiotic therapy.

For prophylaxis in the newborn the suggested dose is 1ml once daily.

The longer the suspension is kept in contact with the affected area in the mouth before swallowing, the greater will be its effect.

Administration should be continued for 48 hours after clinical cure to prevent relapse.

Older people

No specific dosage recommendations or precautions.

If signs and symptoms worsen or persist (beyond 14 days of treatment), the patient should be reevaluated, and alternate therapy considered.

4.3 Contraindications:

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use:

Nystatin Oral Suspension contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. This should also be taken into account in patients with diabetes mellitus.

KENSTATIN		
NYSTATIN ORAL SUSPENSION USP 100000 IU/ML		
MODULE I :	ADMINISTRATIVE PARTICULARS OF THE PRODUCT	
Document	1.3	Product Information

Nystatin Oral Suspension contains 0.3 mmol (or 1.3 mg) sodium per 1 ml dose. To be taken into consideration by patients on a controlled sodium diet.

Nystatin Oral Suspension contains sodium metabisulphite (E223) which may rarely cause severe hypersensitivity reactions and bronchospasm.

Nystatin Oral Suspension contains propyl p-hydroxybenzoate and methyl p-hydroxybenzoate which may cause allergic reactions (possibly delayed).

Nystatin oral preparations should not be used for treatment of systemic mycoses.

4.5 Interaction with other medicinal products and other forms of interaction:

No interaction studies have been performed.

4.6 Fertility, Pregnancy and

lactation: Pregnancy

Animal reproductive studies have not been conducted with Nystatin.

It is not known whether Nystatin can cause foetal harm when administered to a pregnant woman or can affect reproductive capacity; however absorption of nystatin from the gastrointestinal tract is negligible. Nystatin should be prescribed during pregnancy only if the potential benefits to be derived outweigh the possible risks involved.

Breastfeeding

It is not known whether Nystatin is excreted in human milk. Although gastrointestinal absorption is insignificant, caution should be exercised when Nystatin is prescribed for a breast-feeding woman.

4.7 Effects on ability to drive and use machines:

Not relevant.

4.8 Undesirable effects:

Nystatin is generally well tolerated by all age groups, even during prolonged use. If irritation or sensitisation develops, treatment should be discontinued. Nausea has been reported occasionally during therapy.

Large oral doses of Nystatin have occasionally produced diarrhoea, gastrointestinal distress, nausea and vomiting. Rash, including urticaria has been reported rarely. Steven- Johnson Syndrome has been reported very rarely. Hypersensitivity and angioedema, including facial oedema have been reported.

4.9 Overdose:

Since the absorption of nystatin from the gastro-intestinal tract is negligible, overdosage or accidental ingestion causes no systemic toxicity. Oral doses of nystatin in excess of 5 million units daily have caused nausea and gastrointestinal upset.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties:

Pharmacotherapeutic group: Antifungals for topical use,

ATC code: D01AA01

Nystatin is a mixture of antifungal polyenes produced by the growth of certain strains of *Streptomyces noursei*, or by any other means. It consists largely of Nystatin A₁.

Nystatin is active against a wide range of yeasts and yeast-like fungi, including *Candida*

albicans.

***Brussels Laboratories Pvt.
Ltd.***

KENSTATIN		
NYSTATIN ORAL SUSPENSION USP 100000 IU/ML		
MODULE I :	ADMINISTRATIVE PARTICULARS OF THE PRODUCT	
Document	1.3	Product Information

5.2 Pharmacokinetic Properties:

Nystatin is a tetraene macrolide. There is no data available on the pharmacokinetics as it is not absorbed from the gastro-intestinal tract, skin or vagina and most of the use is topical. Microbial growth-inhibiting concentrations have been shown to be in the range 3-6mg/l.

5.3 Preclinical safety data:

No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effect on male or female fertility.

6. Pharmaceutical particulars

6.1 List of Excipients:

Sorbitol 70% Solution BP
Sodium Methyl Paraben
BP Sodium Propyl Paraben
BP Sodium Benzoate BP
Sodium Saccharine BP
Xanthan Gum BP
Glycerin BP
Colloidal Anhydrous Silica BP
Bronopol BP
Flavour Mix Fruit
Flavour Peppermint
Purified Water BP

6.2 Incompatibilities:

None known

6.3 Shelf life:

24 Months

6.4 Special precautions for storage:

Store below 30°C. Keep medicines out of the reach of children.

6.5 Nature and contents of container:

Primary Packaging: 30 ml Amber Pet Bottle.

Secondary Packaging: Such 1 Bottle is packed in printed carton along with printed insert.

6.6 Special precautions for disposal:

No special requirements.

7. REGISTRANT

SANGHARSH LIFECARE PVT. LTD.

A-502/503, Solitair Corporate Park, Near
Divya Bhaskar House, S.G. Highway,

Makarba, Ahmedabad-380051, Gujarat, India.

***Brussels Laboratories Pvt.
Ltd.***

KENSTATIN		
NYSTATIN ORAL SUSPENSION USP 100000 IU/ML		
MODULE I :	ADMINISTRATIVE PARTICULARS OF THE PRODUCT	
Document	1.3	Product Information

8. DATE OF REVISION OF THE TEXT

**9. NAME AND ADDRESS OF
MANUFACTURER BRUSSELS LABORATORIES
PVT. LTD.**

33, Changodar Industrial Estate,
Sarkhej-Bavla Highway, Changodar-382210,
Dist.: Ahmedabad, Gujarat (India).